Hot Investor Mandate 2: European-based Evergreen Fund Investing in Early-stage Therapeutics

~ Next Phase Admin ~ Leave a comment

An evergreen life science venture fund located in Copenhagen, Denmark, established in the autumn of 2009 and wholly owned by a large European corporate currently has DKK 1.6 billion in AUM. The firm has an annual investment capacity of approximately 350 – 400m DKK. Investments are typically around €10 million with reserves to follow, and the firm prefers to take above 10% ownership. The firm invests primarily in Europe and in the USA.

The firm invests exclusively in life sciences, focusing on pharmaceuticals. The firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The firm is open to opportunities in all therapeutic areas and indications. The firm primarily invest in clinical projects and companies with new technology platforms and are particularly interested in specialist product opportunities.

The firm is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US the firm prefers to syndicate with well-established VC investors specialized in life sciences. The firm expects to be actively in communication with management and represented on the supervisory board of portfolio companies. The firm is seeking experienced and capable management teams that are committed to resolving the unmet medical needs. Other requirements are a well-defined plan, a strong and durable patent protection, and a sound understanding of the relevant markets and their regulatory frameworks.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Taiwan-based CVC Investing in Therapeutics and Digital Health

~ Next Phase Admin ~ Leave a comment

A corporate venture of a publicly listed Taiwanese pharmaceutical company now focuses on strategic investments and add-on acquisition for its portfolio companies. Typical allocation size ranges from US$5-20 million. The firm is currently seeking opportunities in Asia and the US.

The CVC is investing strategically for its portfolio companies in select sectors. Within therapeutics, the firm considers small molecules, biologics, antibody-drug conjugates, and gene therapies in oncology. The firm also considers CNS, pain, cardiovascular and metabolic disease, and infectious diseases. The firm typically invests in late preclinical projects to phase 1 trial. Within medical technologies, the firm is interested in innovative digital health innovations.

The firm is looking for experienced management teams with strong scientific expertise and management skills. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Subsidiary Fund of Health Insurance Corporate Investing in Consumer Health Solutions

~ Next Phase Admin ~ Leave a comment

A wholly owned subsidiary of an established private health insurance company seeks to investment in technologies that are a strategic fit with members of the network. The firm is flexible in terms of investment sizes and considers an array of capital structures including equity, convertible note, debt, and others. The firm typically co-invests with other investors but is open to leading a financing round. The firm is currently seeking new opportunities from across the US, while non-US opportunities may also be considered.

The firm is focused on opportunities in the following areas: Accountable Care Organizations, Consumer Solutions; Health Information Technology; and Behavioral Health. Potential examples may include consumer-facing patient engagement software, behavioral health technology, telemedicine, and B2B solutions that help healthcare organizations with decision making and financial planning. The firm is stage agnostic and would consider from pre-revenue to commercial-stage companies. Historically the firm has invested in patient monitoring system, EHR aggregation and analytics, and mobile health information platform.

The firm is seeking experienced, competent teams with disruptive innovations that are a strategic fit with its members. After investment, the firm typically request a board seat or at least an observer position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

There’s Only One Choice If You are in San Diego on June 19th

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

When LSN decided to bring RESI to San Diego, we took note of the rhythm of other events and receptions that take place during BIO week. What did we see? A distinct lull on Monday. That’s the day when we kick off the week, and LSN saw an opportunity to fill that gap with partnering meetings and early stage focused content.

Adding a day full of meetings prior to BIO is sure to make your week more productive, more connected and more fruitful. And to keep you busy between meetings, RESI has 3 tracks of investor panels and early stage workshops to edify and advise you in your fundraising. If you’d like to join us there, it’s not too late – you can sign up now.

1:1 Ratio of Entrepreneurs to Investors at Upcoming RESI Event

~ Next Phase Admin ~ Leave a comment

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-newHow do you get the most out of a day of networking and one-to-one meetings? It’s all about being able to connect with the right partners. At RESI, hundreds of highly innovative early stage companies in drug development, medical devices, diagnostics and healthcare IT come to meet with hundreds of early stage investors focused on those verticals. RESI gathers attendees from not just all over North America, but all over the world. The investors in attendance are very diverse, representing both traditional funding sources like venture capital firms and large pharmas, and also newer sources in early stage investment such as family offices and nonprofit foundations. Via RESI’s uniquely curated Partnering system, attendees can zero in on the most relevant potential investors and ensure that their meetings will have a strong basis in mutual fit. Want to take part?

Register here now

New at RESI San Diego: Genomics Investors in the Spotlight

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, Director of Research, LSN

Genomic innovation cuts across many technology verticals.  The dawn of efficient and inexpensive gene sequencing enabled many breakthrough discoveries in biology by identifying genes that have a role in specific diseases. Patients can now be stratified by genetic subtypes in order to identify the most suitable treatment. Some startups aim to use sequencing to identify future health risks. Meanwhile, sequencing has created massive amounts of genetic data, which could yield many further discoveries with the right curation and analysis.

At RESI, a panel of investors with a focus on genomics will discuss what kind of breakthroughs they are looking to back, and what challenges still remain in the genomics field.

Moderated by Amanda Cashin (Head of Illumina Accelerator), the participants are:

Hot Investor Mandate 1: US Firm Works with China Partner to Invest in Disruptive Life Science Technologies

~ Next Phase Admin ~ Leave a comment

A venture capital firm based in Palo Alto, CA is looking for early stage life science opportunities. The firm also has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in a total of 13 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and healthcare IT, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com